All In Biotech

Drug Trial Radar · NCT07169279

Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)

Phase 2b, Randomized, Double-Blind, Placebo-Controlled Clinical Trial, Preceded by a Single Ascending Dose Portion and a Phase 2 Open-Label Portion, to Evaluate the Safety and Efficacy of Oral Infigratinib in Infants and Young Children With Achondroplasia

Last checked: Nov 20, 2026Latest source record: Jul 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

77

Planned (sponsor's estimate)

Start

Nov 19, 2025

Primary completion

Mar 2030

Study completion Mar 2032

Sponsor

Sponsor type
Industry
First posted
Sep 11, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 0 years, up to 32 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2, multicenter, randomized, placebo-controlled study to evaluate the safety and efficacy of infigratinib in participants \< 3 years old with ACH. The purposes of the SAD and Phase 2 portions are to identify and confirm the dose of infigratinib to be used in the Phase 2b portion, based on safety and PK. The purpose of the Phase 2b, placebo-controlled portion is to evaluate the safety and efficacy of infigratinib in children \< 3 years old with ACH at the selected dose.

Conditions

  • Achondroplasia

Interventions

  • Infigratinib is provided as a single dose of minitablets for oral administrationDrug

    * The initial cohort dose of infigratinib will begin at the protocol-specified starting dose, with subsequent cohort escalation based on protocol specific criteria. * The dose and number of minitablets will be calculated based on individual participant age and weight.

  • Infigratinib is provided as sprinkle capsules for daily oral administrationDrug

    * The cohort dose of infigratinib will be the dose identified in the Single Ascending Dose portion for the age group. * The dose and number of sprinkle capsules/day will be calculated based on individual participant age and weight. Doses will be adjusted based on age and weight changes approximately every 3 months.

  • Infigratinib or placebo comparator is provided as sprinkle capsules for daily oral administrationDrug

    * The cohort dose of infigratinib or placebo will be the dose confirmed in the Phase 2 portion for the age group. * The dose and number of sprinkle capsules/day will be calculated based on individual participant age and weight. Doses will be adjusted based on age and weight changes approximately every 3 months.

  • Infigratinib is provided as sprinkle capsules for daily oral administrationDrug

    * The dose of infigratinib will be the dose confirmed in the Phase 2 portion and used in the Phase 2b portion for the age group. * The dose and number of sprinkle capsules/day will be calculated based on individual participant age and weight. Doses will be adjusted based on age and weight changes approximately every 3 months for the first year and every 6 months thereafter.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Single Ascending Dose Portion: Identify the dose of infigratinib to be used in each age cohort of the Phase 2 potion of the study (by assessing safety and PK of infigratinib and its active metabolites)Time frame: 2 weeks
  2. Phase 2 Portion: Confirm the doses to be used in each age cohort in the Phase 2b portion of the study (by assessing safety and PK of infigratinib and its active metabolites).Time frame: 52 weeks
  3. Phase 2b Portion: Evaluate the safety and efficacy of infigratinib in infants and children < 3 years old with ACH (by assessing AE's & SAE's)Time frame: 52 weeks
  4. Extension Portion: Evaluate the safety and efficacy of infigratinib in participants who completed the Phase 2 or Phase 2b portion of the study until they have reached 3 years old (+6 months) (by assessing AE's and SAE's)Time frame: 3 years and 6 months

Locations

12 sites in 7 countries. Site status is shown where the registry gives one.

  • UCSF Benioff Children's Hospital

    Oakland, California · Recruiting

  • Johns Hopkins University

    Baltimore, Maryland · Recruiting

  • University of Wisconsin Madison - Waisman Center Bone Dysplasia Clinic

    Madison, Wisconsin · Recruiting

  • Murdoch Children's Research Institute

    Parkville, Victoria, Australia · Recruiting

  • Children's Hospital of Eastern Ontario Research Institute

    Ottawa, Ontario, Canada · Recruiting

  • Université de Montréal - Centre Hospitalier Universitaire Sainte-Justine

    Montreal, Quebec, Canada · Recruiting

  • Paediatric Clinical Research Unit at Oslo University Hospital

    Oslo, Norway · Recruiting

  • KK Women's and Children's Hospital

    Singapore, Singapore · Recruiting

  • Unidad de Cirugía Artroscópica (UCA)

    Vitoria-Gasteiz, Spain · Recruiting

  • NHS Greater Glasgow and Clyde

    Glasgow, United Kingdom · Recruiting

  • Manchester University NHS Foundation Trust

    Manchester, United Kingdom · Recruiting

  • Sheffield Children's NHS Foundation Trust

    Sheffield, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.